SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

Summary

This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin, comprising 24 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 52 weeks.

Timeline

Start

2020-05-06

Primary completion

2022-05-24

Completion

2022-05-24

Drugs

Indications